Evidence map›Paper›PMID 37632438›Full record

ReviewThe Journal of international medical research2023

Sclerostin: clinical insights in muscle-bone crosstalk.

Antimo Moretti, Giovanni Iolascon

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07193056 (Chronic Kidney Disease -Mineral and Bone Disorder, The CPH-MBD Cohort), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07193056 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Chronic Kidney Disease -Mineral and Bone Disorder, The CPH-MBD Cohort

Typeobservational_patient_registrySponsorHerlev HospitalRan2025 to 2055Enrolled1,000ConditionsChronic Kidney Disease Mineral and Bone Disorder, Chronic Kidney Disease (CKD), Bone Markers
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Osteosarcopenia in Chronic Kidney Disease: An Overlooked Syndrome?Journal of cachexia, sarcopenia and muscle · 2025
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Antimo MorettiDepartment of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', Naples, Italy.ORCID 0000-0002-4598-2891
Giovanni IolasconDepartment of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', Naples, Italy.ORCID 0000-0002-0976-925X
University of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sclerostin, a protein encoded by the sclerostin (

Indexed as

HyperostosisMusclesAdaptor Proteins, Signal TransducingHumansKnowledgeOsteoblastsOsteogenesisAdaptor Proteins, Signal TransducingSOST protein, humanfallsmuscle massmuscle strengthmyoblastsosteocytesosteoporosisosteosarcopeniaromosozumabSclerostinWnt-pathway

Identifiers

PMID37632438
PMCPMC10467411
OpenAlexW4386193167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.